Cancer remains the second leading cause of death in the industrialised world and its incidence is growing. But if detected early enough, many forms of the disease can be effectively treated. Cancer is not a single, static disease. It is a complex condition of which over 250 types have been identified so far. Its development involves a multitude of changes in the affected cells, and this makes it difficult to fight.
World leader in innovative cancer drugs
Roche currently has a number of innovative cancer drugs on the market. They give patients the most important thing in life: time to live.
Five of these drugs – Herceptin, Avastin, MabThera/Rituxan, Xeloda and Tarceva – offer clear survival benefits in different types of cancer and each has its own unique mechanism of action that halts tumour growth. In addition to these products, we supply a variety of therapies that help to ease the possible side effects associated with cancer treatment.
Precise diagnosis –
The key to successful treatment
Precise diagnosis is the key to successful treatment. Biomarkers, i.e. components of our body cells that can be used as indicators for the disease, will enable doctors to determine which cancer type a patient has much more quickly and specifically.
Roche is also working to identify tumour markers that will detect tumour cells long before the first symptoms become apparent. This information will help physicians to initiate targeted and effective treatment without delay, thereby enhancing patient well-being and decreasing the cost to the healthcare system.
Roche searches for potential cures
Our understanding of the molecular mechanisms of tumour development and how tumours spread has continually improved. This helps our scientists to target the processes that lead to cancer. This is an area where biopharmaceuticals, and especially highly specific antibodies, play an important role. Our goal is to use modern technologies to make these biopharmaceuticals even more effective in the future.